Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4898676 | 0.93 | KDM4E (0.50) | KDM4EHSD17B10RAB9AHTTNPSR1 | |
| SCHEMBL14103623 | 0.92 | KDM4E (0.44) | KDM4EHSD17B10RAB9AHTTNPSR1 | |
| SCHEMBL4887003 | 0.86 | HTT (0.57) | HTTNPSR1POLBALDH1A1KMT2A | |
| SCHEMBL4893569 | 0.85 | POLB (0.40) | KDM4EHTTNPSR1POLBALDH1A1 | |
| SCHEMBL4892536 | 0.83 | ALDH1A1 (0.54) | KDM4EHSD17B10RAB9AHTTPOLB | |
| SCHEMBL4883902 | 0.82 | KDM4E (0.46) | KDM4EHSD17B10RAB9AHTTNPSR1 | |
| SCHEMBL4892453 | 0.82 | HTT (0.46) | KDM4EHSD17B10HTTNPSR1POLB | |
| SCHEMBL4895640 | 0.81 | KDM4E (0.53) | KDM4EHSD17B10RAB9APOLBALDH1A1 | |
| SCHEMBL14087778 | 0.81 | POLB (0.37) | KDM4EHSD17B10RAB9AHTTNPSR1 | |
| SCHEMBL14087795 | 0.79 | HTT (0.42) | KDM4ERAB9AHTTNPSR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | SSU72, POLR2H, POLR2E | KDM4E 2519/4885HSD17B10 240/4885RAB9A 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.